Ping Fan,V Craig Jordan
Ping Fan
The translational research strategy of targeting estrogen receptor α (ERα) positive breast cancer and then using long term anti-hormone adjuvant therapy (5-10 years) has reduced recurrences and mortality. However, resistance continues to ...
Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas [0.03%]
识别并靶向CD22ΔE12作为针对高危B细胞白血病和淋巴瘤药物抵抗的分子RNAi靶点
Fatih M Uckun,Sanjive Qazi
Fatih M Uckun
Aim: CD22ΔE12 as an oncogenic driver lesion in aggressive and drug-resistant B-precursor acute lymphoblastic leukemia (BPL) cells. The purpose of the present study was to identify the CD22ΔE12-specific signature transcr...
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors [0.03%]
睾丸生殖细胞肿瘤顺铂敏感和耐药的机制
Ratnakar Singh,Zeeshan Fazal,Sarah J Freemantle et al.
Ratnakar Singh et al.
Testicular germ cell tumors (TGCTs) are a cancer pharmacology success story with a majority of patients cured even in the highly advanced and metastatic setting. Successful treatment of TGCTs is primarily due to the exquisite responsiveness...
Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses [0.03%]
将酪氨酸激酶抑制剂介导的炎症与正常上皮细胞稳态和肿瘤治疗反应联系起来
Natalia J Gurule,Lynn E Heasley
Natalia J Gurule
Receptor tyrosine kinases (RTKs) bearing oncogenic mutations in EGFR, ALK and ROS1 occur in a significant subset of lung adenocarcinomas. Tyrosine kinase inhibitors (TKIs) targeting tumor cells dependent on these oncogenic RTKs yield tumor ...
Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations [0.03%]
具有p53突变的结直肠癌细胞中F10相对5-氟尿嘧啶活性增强
Anthony Dominijanni,William H Gmeiner
Anthony Dominijanni
Aim: Resistance to fluoropyrimidine drugs (FPs) is a major cause of mortality in colorectal cancer (CRC). We assessed the potency advantage of the polymeric FP F10 relative to 5-fluorouracil (5FU) in four human CRC cell l...